BioCryst Pharmaceuticals (BCRX) is back in focus after raising its full year 2026 revenue outlook, reporting detailed second quarter earnings, and highlighting progress across its hereditary angioedema and rare disease pipeline. See our latest analysis for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' recent guidance upgrade and second quarter earnings are arriving alongside a 7 day share price return of 16.76% and a year to date share price return of 41.20%. However, the 5 year total...

BioCryst Pharmaceuticals stock has put up a 53.0% gain over the past three years, yet the current valuation checks still lean on the inexpensive side for this kind of run. That mix raises the question of whether the recent share price is keeping up with what the broader indicators suggest about value. Over the past three years the share price return of 53.0% points to investors already recognising progress at BioCryst Pharmaceuticals, which can limit how much easy upside is left. Revenue...

ORLADEYO revenue hit $158.2M with 10% growth as pediatric launch exceeded expectations.

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Investors need to pay close attention to BCRX stock based on the movements in the options market lately.

BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by letting someone else snap it up first?

BioCryst Pharmaceuticals Inc (BCRX) reports 45% revenue growth, strong Orladeo performance, and a strategic shift toward external pipeline development.

Moby summary of BioCryst Pharmaceuticals, Inc.'s Q2 2026 earnings call

BioCryst raised its full-year 2026 total revenue outlook to $690 million to $715 million, up from its previous estimates of $635 million to $660 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE. President and CEO Charlie Ga

BioCryst (BCRX) delivered earnings and revenue surprises of +114.29% and +18.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.